BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22856430)

  • 1. Targeting the regulatory machinery of BIM for cancer therapy.
    Harada H; Grant S
    Crit Rev Eukaryot Gene Expr; 2012; 22(2):117-29. PubMed ID: 22856430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
    Chen S; Dai Y; Pei XY; Grant S
    Mol Cell Biol; 2009 Dec; 29(23):6149-69. PubMed ID: 19805519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
    Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
    Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABT-737 induces Bim expression via JNK signaling pathway and its effect on the radiation sensitivity of HeLa cells.
    Wang H; Yang YB; Shen HM; Gu J; Li T; Li XM
    PLoS One; 2012; 7(12):e52483. PubMed ID: 23285061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström macroglobulinemia.
    Gaudette BT; Dwivedi B; Chitta KS; Poulain S; Powell D; Vertino P; Leleu X; Lonial S; Chanan-Khan AA; Kowalski J; Boise LH
    Oncogene; 2016 Jan; 35(4):479-90. PubMed ID: 25893290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
    Huang S; Sinicrope FA
    Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PUMA and BIM are required for oncogene inactivation-induced apoptosis.
    Bean GR; Ganesan YT; Dong Y; Takeda S; Liu H; Chan PM; Huang Y; Chodosh LA; Zambetti GP; Hsieh JJ; Cheng EH
    Sci Signal; 2013 Mar; 6(268):ra20. PubMed ID: 23532334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G₁ cell-cycle arrest and not a direct effect on BIK protein stability.
    Sale MJ; Cook SJ
    Biochem J; 2014 May; 459(3):513-24. PubMed ID: 24527759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
    Woo SM; Min KJ; Seo BR; Nam JO; Choi KS; Yoo YH; Kwon TK
    Cell Death Dis; 2014 Nov; 5(11):e1514. PubMed ID: 25375379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.
    Deng J; Carlson N; Takeyama K; Dal Cin P; Shipp M; Letai A
    Cancer Cell; 2007 Aug; 12(2):171-85. PubMed ID: 17692808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome.
    Niss O; Sholl A; Bleesing JJ; Hildeman DA
    J Allergy Clin Immunol; 2015 Mar; 135(3):762-70. PubMed ID: 25174872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim.
    Paschos K; Smith P; Anderton E; Middeldorp JM; White RE; Allday MJ
    PLoS Pathog; 2009 Jun; 5(6):e1000492. PubMed ID: 19557159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms.
    De Bruyne E; Bos TJ; Schuit F; Van Valckenborgh E; Menu E; Thorrez L; Atadja P; Jernberg-Wiklund H; Vanderkerken K
    Blood; 2010 Mar; 115(12):2430-40. PubMed ID: 20086250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
    Cragg MS; Kuroda J; Puthalakath H; Huang DC; Strasser A
    PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
    Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FoxO proteins' nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells.
    Shukla S; Rizvi F; Raisuddin S; Kakkar P
    Free Radic Biol Med; 2014 Nov; 76():185-99. PubMed ID: 25128467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
    Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
    Pei XY; Dai Y; Tenorio S; Lu J; Harada H; Dent P; Grant S
    Blood; 2007 Sep; 110(6):2092-101. PubMed ID: 17540843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melatonin induces transcriptional regulation of Bim by FoxO3a in HepG2 cells.
    Carbajo-Pescador S; Steinmetz C; Kashyap A; Lorenz S; Mauriz JL; Heise M; Galle PR; González-Gallego J; Strand S
    Br J Cancer; 2013 Feb; 108(2):442-9. PubMed ID: 23257900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.